The Protein Kinase C Theta Type pipeline drugs market research report outlays comprehensive information on the Protein Kinase C Theta Type targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Protein Kinase C Theta Type pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Undisclosed, and Metabolic Disorders which include the indications Unspecified Cancer, Prostate Cancer, Psoriasis, Autoimmune Disorders, Unspecified, Obesity, and Type 2 Diabetes. It also reviews key players involved in Protein Kinase C Theta Type targeted therapeutics development with respective active and dormant or discontinued products.
The Protein Kinase C Theta Type pipeline targets constitutes close to nine molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 3, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Protein Kinase C Theta Type overview
Protein kinase C theta (PKC-θ) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-costimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway.
For a complete picture of Protein Kinase C Theta Type’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
